Adequate tacrolimus concentration for myasthenia gravis treatment

Background and purpose A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis (MG) treatment in Japan, was shown to reduce steroid dose and anti‐acetylcholine receptor (AChR) antibody titers as well as to improve MG symptoms. However, no studies have investigated the association...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2017-02, Vol.24 (2), p.270-275
Hauptverfasser:	Kanai, T., Uzawa, A., Kawaguchi, N., Himuro, K., Oda, F., Ozawa, Y., Kuwabara, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Autoantibodies - immunology Dose-Response Relationship, Drug Drug Therapy, Combination Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Japan Kinases Male Middle Aged minimal manifestation myasthenia gravis Myasthenia Gravis - drug therapy Prednisolone - therapeutic use Prognosis Retrospective Studies Tacrolimus - administration & dosage Tacrolimus - therapeutic use tacrolimus concentration Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!